| abstract |
The present invention is directed, in part, to a selective cancer treatment regime based on assaying the presence or absence of PI3K mutations in blood or serum samples obtained from patients with cancer. The cancer is 5- (2,6-di-morpholin-4-yl-pyrimidin-4-yl) -4-trifluoromethyl-pyridin-2-ylamine or its hydrochloride, or (S) -pyrrolidin-1, 2-Dicarboxylic acid 2-amide 1-({4-methyl-5- [2- (2,2,2-trifluoro-1,1-dimethyl-ethyl) -pyridin-4-yl] -thiazol-2- Il} -amide). |